Menu

Infographic: Nanostraw Extraction

Researchers devise a way to sample living proteins and RNAs from cells by using an electric current to briefly open pores in the membrane.

Sep 30, 2017
Ruth Williams

© GEORGE RETSECK

Cells are cultured atop a polycarbonate membrane perforated in spots by vertical aluminum oxide nanostraws. At defined locations, where the membrane has been etched away lithographically, the nanostraws protrude from the membrane and contact the cells. A brief electric voltage is passed across the nanostraws, causing temporary perforations in the cell membrane. This allows small volumes of cytoplasm to diffuse into the nanostraws for collection in the reservoir of extraction buffer below the polycarbonate membrane.

Read the full story.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.